Multitarget ligands and theranostics: Sharpening the medicinal chemistry sword against prion diseases

Future Medicinal Chemistry

Volumn 6, Issue 9, 2014, Pages 1017-1029

  Bongarzone, Salvatore ^a,b   Staderini, Matteo ^c   Bolognesi, Maria Laura ^d  

^a INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^b INSTITUT DE BIOLOGIA MOLECULAR DE BARCELONA   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

bivalent ligands; Creutzfeldt Jakob disease; prion drug discovery; protein misfolding diseases; rare diseases

Indexed keywords

ACRIDINE; ALPHA SYNUCLEIN; AMYLOID; AMYLOID BETA PROTEIN; ANTIOXIDANT; CONGO RED; FLUORESCENT DYE; LIGAND; MULTITARGET LIGAND; PIPERAZINEDIONE; PRION PROTEIN; QUINOLINE; REACTIVE OXYGEN METABOLITE; TACRINE DERIVATIVE; THERANOSTIC LIGAND; THIOCTIC ACID; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; CHEMICAL COMPOSITION; CHEMICAL STRUCTURE; FLUORESCENCE SPECTROSCOPY; HUMAN; HYDROGEN BOND; MEDICINAL CHEMISTRY; MOLECULAR IMAGING; MOLECULAR RECOGNITION; NEAR INFRARED SPECTROSCOPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PHARMACOPHORE; POSITRON EMISSION TOMOGRAPHY; PRION DISEASE; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN MISFOLDING; PROTEIN PROTEIN INTERACTION; REVIEW; DRUG DEVELOPMENT; GENETICS; PRION DISEASES;

CHEMISTRY, PHARMACEUTICAL; DRUG DISCOVERY; HUMANS; LIGANDS; PRION DISEASES;

EID: 84905162939     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.14.56     Document Type: Review

References (128)

1. Aguzzi A. Prion diseases of humans and farm animals: epidemiology, genetics, and pathogenesis. J. Neurochem. 97(6), 1726-1739 (2006).
2. Collinge J. Prion diseases of humans and animals: their causes and molecular basis. Annu. Rev. Neurosci. 24, 519-550 (2001).
3. Legname G, Laura Bolognesi M. Thematic issue: recent advances of biology and medicinal chemistry of prion protein and prions: on the road to therapeutics. Curr. Top. Med. Chem. 13(19), 2395-2396 (2013).
4. Soto C. Prion hypothesis: the end of the controversy? Trends Biochem. Sci. 36(3), 151-158 (2011).
5. Prusiner SB. Prions. Proc. Natl. Acad. Sci. USA 95(23), 13363-13383 (1998).
6. Kovacs GG, Budka H. Prion diseases: from protein to cell pathology. Am. J. Pathol. 172(3), 555-565 (2008).
7. Lloyd S, Mead S, Collinge J. Genetics of prion disease. Top. Curr. Chem. 305, 1-22 (2011).
8. Aguzzi A, Calella AM. Prions: protein aggregation and infectious diseases. Physiol. Rev. 89(4), 1105-1152 (2009).
9. Aguzzi A, Steele AD. Prion topology and toxicity. Cell 137(6), 994-996 (2009).
10. Dormont D. Prion diseases: pathogenesis and public health concerns. FEBS Lett. 529(1), 17-21 (2002).
11. The national CJD research and surveillance unit. www.cjd.ed.ac.uk
12. Prusiner SB. Cell biology. A unifying role for prions in neurodegenerative diseases. Science 336(6088),1511-1513 (2012).
13. Miller G. Could They all be prion diseases? Science 326(5958),1337-1339 (2009).
14. Lahiri DK. Prions: a piece of the puzzle? Science 337(6099), 1172 (2012).
15. Jucker M, Walker LC. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 501(7465),45-51 (2013).
16. Chen B, Thompson M, Louth J, Guo K. Prion chemical biology: on the road to therapeutics? Curr. Top. Med. Chem. 13(19), 2441-2464 (2013).
17. Pangalos MN, Schechter LE, Hurko O. Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nat. Rev. Drug Discov. 6(7), 521-532 (2007).
18. Enna SJ, Williams M. Challenges in the search for drugs to treat central nervous system disorders. J. Pharmacol. Exp. Ther. 329(2), 404-411 (2009).
19. Markou A, Chiamulera C, Geyer MA, Tricklebank M, Steckler T. Removing obstacles in neuroscience drug discovery: the future path for animal models. Neuropsychopharmacology 34(1), 74-89 (2009).
20. Becker RE, Greig NH. Increasing the success rate for Alzheimer's disease drug discovery and development. Expert Opin. Drug Discov. 7(4), 367-370 (2012).
21. Bolognesi ML, Melchiorre C, Van Der Schyf CJ, Youdim M. Discovery of multi-target agents for neurological diseases via ligand design. In: Designing Multi-Target Drugs. Morphy JR, Harris CJ (Eds). The Royal Society of Chemistry, London, UK, 290-315 (2012).
22. Chen X, Decker M. Multi-target compounds acting in the central nervous system designed from natural products. Curr. Med. Chem. 20(13), 1673-1685 (2013).
23. Cavalli A, Bolognesi ML, Minarini A et al. Multi-target-directed ligands to combat neurodegenerative diseases. J. Med. Chem. 51(3), 347-372 (2008).
24. Geldenhuys WJ, Youdim MB, Carroll RT, Van Der Schyf CJ. The emergence of designed multiple ligands for neurodegenerative disorders. Prog. Neurobiol. 94(4), 347-359 (2011).
25. Leon R, Garcia AG, Marco-Contelles J. Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease. Med. Res. Rev. 33(1), 139-189 (2013).
26. Munoz-Torrero D. Complexity against complexity: multitarget drugs. Curr. Med. Chem. 20(13), 1621-1622 (2013).
27. Cavalli A, Bolognesi ML. Multitargeted drugs for treatment of alzheimer's disease. In: Polypharmacology in Drug Discovery. Peters JU (Ed.). John Wiley & Sons, Inc., NJ, USA, 441-458 (2012).
28. Kelkar SS, Reineke TM. Theranostics: combining imaging and therapy. Bioconjug. Chem. 22(10), 1879-1903 (2011).
29. Lammers T, Aime S, Hennink WE, Storm G, Kiessling F. Theranostic nanomedicine. Acc. Chem. Res. 44(10), 1029-1038 (2011).
30. Bolognesi ML. Amyloid chemical probes and theranostics: steps toward personalized medicine in neurodegenerative diseases. In: Medicinal Chemistry Approaches to Personalized Medicine. Lackey K, Roth BD (Eds). Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany, 211-226 (2013).
31. Soto C, Satani N. The intricate mechanisms of neurodegeneration in prion diseases. Trends Mol. Med.17(1), 14-24 (2011).
32. Trevitt CR, Collinge J. A systematic review of prion therapeutics in experimental models. Brain 129(Pt 9), 2241-2265 (2006).
33. Gavrin LK, Denny RA, Saiah E. Small molecules that target protein misfolding. J. Med. Chem. 55(24), 10823-10843 (2012).
34. Kranjc A, Bongarzone S, Rossetti G et al. Docking ligands on protein surfaces: the case study of prion protein. J. Chem. Theory Comput. 5(9), 2565-2573 (2009).
35. Brown DR. Prion protein peptides: optimal toxicity and peptide blockade of toxicity. Mol. Cell Neurosci. 15(1), 66-78 (2000).
36. Perez M, Sadqi M, Munoz V, Avila J. Inhibition by aplidine of the aggregation of the prion peptide PrP 106-126 into beta-sheet fibrils. Biochim. Biophys. Acta 1639(2), 133-139 (2003).
37. Vilches S, Vergara C, Nicolas O et al. Neurotoxicity of prion peptides mimicking the central domain of the cellular prion protein. PLoS ONE 8(8), e70881 (2013).
38. Wang X, He L, Zhao C, Du W, Lin J. Gold complexes inhibit the aggregation of prion neuropeptides. J. Biol. Inorg. Chem. 18(7), 767-778 (2013).
39. Wang Y, Feng L, Zhang B et al. Palladium complexes affect the aggregation of human prion protein PrP106-126. Inorg. Chem. 50(10), 4340-4348 (2011).
40. Keunhong J, Junghun S, Woo Young C, Young Sik K, Dongwook K, Tae Yeon L. New methodology for estimation of the prion protein 106-126 amyloid aggregation. Bull. Korean Chem. Soc. 31(4), 1029-1030 (2010).
41. Baral PK, Swayampakula M, Rout MK et al. Structural basis of prion inhibition by phenothiazine compounds. Structure 22(2), 291-303 (2014).
42. Staderini M, Legname G, Bolognesi ML, Menendez JC. Modulation of prion by small molecules: from monovalent to bivalent and multivalent ligands. Curr. Top. Med. Chem. 13(19), 2491-2503 (2013).
43. Horton DA, Bourne GT, Smythe ML. Exploring privileged structures: the combinatorial synthesis of cyclic peptides. J. Comput. Aided Mol. Des. 16(5-6), 415-430 (2002).
44. Bolognesi ML, Ai Tran HN, Staderini M et al. Discovery of a class of diketopiperazines as antiprion compounds. Chem Med Chem 5(8), 1324-1334 (2010).
45. Bongarzone S, Bolognesi ML. The concept of privileged structures in rational drug design: focus on acridine and quinoline scaffolds in neurodegenerative and protozoan diseases. Expert Opin. Drug Discov. 6(3), 251-268 (2011).
46. Tran HN, Bongarzone S, Carloni P, Legname G, Bolognesi ML. Synthesis and evaluation of a library of 2,5-bisdiaminobenzoquinone derivatives as probes to modulate protein-protein interactions in prions. Bioorg. Med. Chem. Lett. 20(6), 1866-1868 (2010).
47. Azriel R, Gazit E. Analysis of the minimal amyloid-forming fragment of the islet amyloid polypeptide. An experimental support for the key role of the phenylalanine residue in amyloid formation. J. Biol. Chem. 276(36), 34156-34161 (2001).
48. Bartolini M, Bertucci C, Bolognesi ML, Cavalli A, Melchiorre C, Andrisano V. Insight into the kinetic of amyloid beta (1-42) peptide self-aggregation: elucidation of inhibitors' mechanism of action. Chembiochem 8(17), 2152-2161 (2007).
49. Bongarzone S, Tran HN, Cavalli A et al. Parallel synthesis, evaluation, and preliminary structure-activity relationship of 2,5-diamino-1,4-benzoquinones as a novel class of bivalent antiprion compound. J. Med. Chem. 53(22), 8197-8201 (2010).
50. Colby DW, Zhang Q, Wang S et al. Prion detection by an amyloid seeding assay. Proc. Natl Acad. Sci. USA 104(52), 20914-20919 (2007).
51. Petrelli A, Valabrega G. Multitarget drugs: the present and the future of cancer therapy. Expert Opin. Pharmacother. 10(4), 589-600 (2009).
52. Millan MJ. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol. Ther. 110(2), 135-370 (2006).
53. Wong EH, Tarazi FI, Shahid M. The effectiveness of multi-target agents in schizophrenia and mood disorders: relevance of receptor signature to clinical action. Pharmacol. Ther. 126(2), 173-185 (2010).
54. Youdim MB, Kupershmidt L, Amit T, Weinreb O. Promises of novel multi-target neuroprotective and neurorestorative drugs for Parkinson's disease. Parkinsonism Relat. Disord. 20(Suppl. 1), S132-S136 (2014).
55. Youdim MB. Multi target neuroprotective and neurorestorative anti-Parkinson and anti-Alzheimer drugs ladostigil and m30 derived from rasagiline. Exp. Neurobiol. 22(1), 1-10 (2013).
56. Morphy R. Selective multitargeted drugs. In: Polypharmacology in Drug Discovery, Peters J-U (Ed.). John Wiley & Sons, Inc., NJ, USA, 245-262 (2012).
57. Morphy JR, Harris CJ. Designing multi-target drugs. In: RSC Drug Discovery. Royal Society of Chemistry, Cambridge, UK (2012).
58. Morphy R, Rankovic Z. The physicochemical challenges of designing multiple ligands. J. Med. Chem. 49(16), 4961-4970 (2006).
59. Das N, Dhanawat M, Dash B, Nagarwal RC, Shrivastava SK. Codrug: an efficient approach for drug optimization. Eur. J. Pharm. Sci. 41(5), 571-588 (2010).
60. Portoghese PS. From models to molecules: opioid receptor dimers, bivalent ligands, and selective opioid receptor probes. J. Med. Chem. 44(14), 2259-2269 (2001).
61. Bhushan RG, Sharma SK, Xie Z, Daniels DJ, Portoghese PS. A bivalent ligand (KDN-21) reveals spinal delta and kappa opioid receptors are organized as heterodimers that give rise to delta(1) and kappa(2) phenotypes. Selective targeting of delta-kappa heterodimers. J. Med. Chem. 47(12), 2969-2972 (2004).
62. Morphy R, Kay C, Rankovic Z. From magic bullets to designed multiple ligands. Drug Discov. Today 9(15), 641-651 (2004).
63. Morphy R, Rankovic Z. Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem. 48(21), 6523-6543 (2005).
64. Morphy R, Rankovic Z. Fragments, network biology and designing multiple ligands. Drug Discov. Today 12(3-4), 156-160 (2007).
65. Morphy R, Rankovic Z. Designing multiple ligands-medicinal chemistry strategies and challenges. Curr. Pharm. Des. 15(6), 587-600 (2009).
66. Caughey B, Baron GS. Prions and their partners in crime. Nature 443(7113),803-810 (2006).
67. Legname G, Baskakov IV, Nguyen HO et al. Synthetic mammalian prions. Science 305(5684), 673-676 (2004).
68. Arlt S, Kontush A, Zerr I et al. Increased lipid peroxidation in cerebrospinal fluid and plasma from patients with Creutzfeldt-Jakob disease. Neurobiol. Dis. 10(2), 150-156 (2002).
69. Klamt F, Dal-Pizzol F, Conte Da Frota ML Jr et al. Imbalance of antioxidant defense in mice lacking cellular prion protein. Free Radic. Biol. Med. 30(10), 1137-1144 (2001).
70. Freixes M, Rodriguez A, Dalfo E, Ferrer I. Oxidation, glycoxidation, lipoxidation, nitration, and responses to oxidative stress in the cerebral cortex in Creutzfeldt-Jakob disease. Neurobiol. Aging 27(12), 1807-1815 (2006).
71. Milhavet O, Mcmahon HE, Rachidi W et al. Prion infection impairs the cellular response to oxidative stress. Proc. Natl Acad. Sci. USA 97(25), 13937-13942 (2000).
72. Pamplona R, Naudi A, Gavin R et al. Increased oxidation, glycoxidation, and lipoxidation of brain proteins in prion disease. Free Radic. Biol. Med. 45(8), 1159-1166 (2008).
73. Singh N, Singh A, Das D, Mohan ML. Redox control of prion and disease pathogenesis. Antioxid. Redox Signal 12(11), 1271-1294 (2010).
74. Lehmann S. Metal ions and prion diseases. Curr. Opin. Chem. Biol. 6(2), 187-192 (2002).
75. Perry VH, Cunningham C, Boche D. Atypical inflammation in the central nervous system in prion disease. Curr. Opin. Neurol. 15(3), 349-354 (2002).
76. Mallucci G, Collinge J. Rational targeting for prion therapeutics. Nat. Rev. Neurosci. 6(1), 23-34 (2005).
77. Nicoll AJ, Collinge J. Preventing prion pathogenicity by targeting the cellular prion protein. Infect. Disord. Drug Targets 9(1), 48-57 (2009).
78. Stewart LA, Rydzewska LH, Keogh GF, Knight RS. Systematic review of therapeutic interventions in human prion disease. Neurology 70(15), 1272-1281 (2008).
79. Caughey B, Caughey WS, Kocisko DA, Lee KS, Silveira JR, Morrey JD. Prions and transmissible spongiform encephalopathy (TSE) chemotherapeutics: a common mechanism for anti-TSE compounds? Acc. Chem. Res. 39(9), 646-653 (2006).
80. Krammer C, Vorberg I, Schatzl HM, Gilch S. Therapy in prion diseases: from molecular and cellular biology to therapeutic targets. Infect. Disord. Drug Targets 9(1), 3-14 (2009).
81. Ludewigs H, Zuber C, Vana K, Nikles D, Zerr I, Weiss S. Therapeutic approaches for prion disorders. Expert Rev. Anti Infect. Ther. 5(4), 613-630 (2007).
82. Sim VL, Caughey B. Recent advances in prion chemotherapeutics. Infect. Disord. Drug Targets 9(1), 81-91 (2009).
83. Wisniewski T, Sigurdsson EM. Therapeutic approaches for prion and Alzheimer's diseases. FEBS J. 274(15), 3784-3798 (2007).
84. Nunziante M, Gilch S, Schatzl HM. Prion diseases: from molecular biology to intervention strategies. Chembiochem 4(12), 1268-1284 (2003).
85. Cope H, Mutter R, Heal W et al. Synthesis and SAR study of acridine, 2-methylquinoline and 2-phenylquinazoline analogues as antiprion agents. Eur. J. Med. Chem. 41(10), 1124-1143 (2006).
86. Guo K, Mutter R, Heal W et al. Synthesis and evaluation of a focused library of pyridine dicarbonitriles against prion disease. Eur. J. Med. Chem. 43(1), 93-106 (2008).
87. Heal W, Thompson MJ, Mutter R, Cope H, Louth JC, Chen B. Library synthesis and screening: 2,4-diphenylthiazoles and 2,4-diphenyloxazoles as potential novel prion disease therapeutics. J. Med. Chem. 50(6), 1347-1353 (2007).
88. Kuwata K, Nishida N, Matsumoto T et al. Hot spots in prion protein for pathogenic conversion. Proc. Natl Acad. Sci. USA 104(29), 11921-11926 (2007).
89. Rossetti G, Bongarzone S, Carloni P. Computational studies on the prion protein. Curr. Top. Med. Chem. 13(19), 2419-2431 (2013).
90. Macedo B, Kaschula CH, Hunter R et al. Synthesis and antiprion activity evaluation of aminoquinoline analogues. Eur. J. Med. Chem. 45(11), 5468-5473 (2010).
91. May BC, Fafarman AT, Hong SB et al. Potent inhibition of scrapie prion replication in cultured cells by bis-acridines. Proc. Natl Acad. Sci. USA 100(6), 3416-3421 (2003).
92. Dollinger S, Lober S, Klingenstein R, Korth C, Gmeiner P. A chimeric ligand approach leading to potent antiprion active acridine derivatives: design, synthesis, and biological investigations. J. Med. Chem. 49(22), 6591-6595 (2006).
93. Choi SI, Ju WK, Choi EK et al. Mitochondrial dysfunction induced by oxidative stress in the brains of hamsters infected with the 263 K scrapie agent. Acta Neuropathol. 96(3), 279-286 (1998).
94. Milhavet O, Lehmann S. Oxidative stress and the prion protein in transmissible spongiform encephalopathies. Brain Res. Brain Res. Rev. 38(3), 328-339 (2002).
95. Gilgun-Sherki Y, Melamed E, Offen D. Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier. Neuropharmacology 40(8), 959-975 (2001).
96. Sinatra ST, Demarco J. Free radicals, oxidative stress, oxidized low density lipoprotein (LDL), and the heart: antioxidants and other strategies to limit cardiovascular damage. Conn. Med. 59(10), 579-588 (1995).
97. Uttara B, Singh AV, Zamboni P, Mahajan RT. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr. Neuropharmacol. 7(1), 65-74 (2009).
98. Bolognesi ML, Minarini A, Tumiatti V, Melchiorre C. Lipoic acid, a lead structure for multi-target-directed drugs for neurodegeneration. Mini Rev. Med. Chem. 6(11), 1269-1274 (2006).
99. Suh JH, Moreau R, Heath SH, Hagen TM. Dietary supplementation with (R)-alpha-lipoic acid reverses the age-related accumulation of iron and depletion of antioxidants in the rat cerebral cortex. Redox Rep. 10(1), 52-60 (2005).
100. Drisko JA. The use of antioxidants in transmissible spongiform encephalopathies: a case report. J. Am. Coll. Nutr. 21(1), 22-25 (2002).
101. Zhang L, Xing GQ, Barker JL et al. Alpha-lipoic acid protects rat cortical neurons against cell death induced by amyloid and hydrogen peroxide through the Akt signalling pathway. Neurosci. Lett. 312(3), 125-128 (2001).
102. Smith AR, Shenvi SV, Widlansky M, Suh JH, Hagen TM. Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. Curr. Med. Chem. 11(9), 1135-1146 (2004).
103. Rosini M, Andrisano V, Bartolini M et al. Rational approach to discover multipotent anti-Alzheimer drugs. J. Med. Chem. 48(2), 360-363 (2005).
104. Bolognesi ML, Cavalli A, Bergamini C et al. Toward a rational design of multitarget-directed antioxidants: merging memoquin and lipoic acid molecular frameworks. J. Med. Chem. 52(23), 7883-7886 (2009).
105. Bongarzone S, Tran HN, Cavalli A et al. Hybrid lipoic acid derivatives to attack prion disease on multiple fronts. Chem Med Chem 6(4), 601-605 (2011).
106. Tateishi J, Kitamoto T. Developments in diagnosis for prion diseases. Br. Med. Bull. 49(4), 971-979 (1993).
107. Schulz-Schaeffer WJ, Tschoke S, Kranefuss N et al. The paraffin-embedded tissue blot detects PrP(Sc) early in the incubation time in prion diseases. Am. J. Pathol. 156(1), 51-56 (2000).
108. Aulic S, Bolognesi ML, Legname G. Small-molecule theranostic probes: a promising future in neurodegenerative diseases. Int. J. Cell Biol. 2013,150952 (2013).
109. Terreno E, Uggeri F, Aime S. Image guided therapy: the advent of theranostic agents. J. Control. Release 161(2), 328-337 (2012).
110. Andrieux K, Couvreur P. Nanomedicine as a promising approach for the treatment and diagnosis of brain diseases: the example of Alzheimer's disease. Ann. Pharm. Fr. 71(4), 225-233 (2013).
111. Raji CA, Becker JT, Tsopelas ND et al. Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer's disease with Pittsburgh compound B. J. Neurosci. Methods 172(2), 277-282 (2008).
112. Rowe CC, Ackerman U, Browne W et al. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 7(2), 129-135 (2008).
113. Choi SR, Golding G, Zhuang Z et al. Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. J. Nucl. Med. 50(11), 1887-1894 (2009).
114. Bertoncini CW, Celej MS. Small molecule fluorescent probes for the detection of amyloid self-assembly in vitro and in vivo. Curr. Protein Pept. Sci. 12(3), 205-220 (2011).
115. Hintersteiner M, Enz A, Frey P et al. In vivo detection of amyloid-beta deposits by near-infrared imaging using an oxazine-derivative probe. Nat. Biotechnol. 23(5), 577-583 (2005).
116. Ran C, Xu X, Raymond SB et al. Design, synthesis, and testing of difluoroboron-derivatized curcumins as near-infrared probes for in vivo detection of amyloid-beta deposits. J. Am. Chem. Soc. 131(42), 15257-15261 (2009).
117. Schmidt A, Pahnke J. Efficient near-infrared in vivo imaging of amyoid-beta deposits in Alzheimer's disease mouse models. J. Alzheimers Dis. 30(3), 651-664 (2012).
118. Nesterov EE, Skoch J, Hyman BT, Klunk WE, Bacskai BJ, Swager TM. In vivo optical imaging of amyloid aggregates in brain: design of fluorescent markers. Angew. Chem. Int. Ed. Engl. 44(34), 5452-5456 (2005).
119. Weissleder R, Pittet MJ. Imaging in the era of molecular oncology. Nature 452(7187),580-589 (2008).
120. Ishikawa K, Doh-Ura K, Kudo Y et al. Amyloid imaging probes are useful for detection of prion plaques and treatment of transmissible spongiform encephalopathies. J. Gen. Vir. 85(6), 1785-1790 (2004).
121. Teruya K, Doh-Ura K. Amyloid-binding compounds and their antiprion potency. Curr. Top. Med. Chem. 13(19), 2522-2532 (2013).
122. Staderini M, Aulic S, Bartolini M et al. A fluorescent styrylquinoline with combined therapeutic and diagnostic activities against Alzheimer's and prion diseases. ACS Med. Chem. Lett. 4(2), 225-229 (2012).
123. Raymond SB, Skoch J, Hills ID, Nesterov EE, Swager TM, Bacskai BJ. Smart optical probes for near-infrared fluorescence imaging of Alzheimer's disease pathology. Eur. J. Nucl. Med. Mol. Imaging 35(Suppl. 1), S93-S98 (2008).
124. Cook NP, Ozbil M, Katsampes C, Prabhakar R, Marti AA. Unraveling the photoluminescence response of light-switching ruthenium(II) complexes bound to amyloid-beta. J. Am. Chem. Soc. 135(29), 10810-10816 (2013).
125. Olivier C, Williams-Jones B, Godard B, Mikalson B, Ozdemir V. Personalized medicine, bioethics and social responsibilities: re-thinking the pharmaceutical industry to remedy inequities in patient care and international health. Curr. Pharmacogenomics Person. Med. 6(2), 108-120 (2008).
126. Merck and Luminex Corporation Enter Agreement to Develop Companion Diagnostic to Support Investigational BACE inhibitor Clinical Development Program for Alzheimer's Disease. www.merck.com/licensing/our-partnership/ luminex-partnership.html
127. Prusiner SB. Detecting mad cow disease. Sci. Am. 291(1), 86-93 (2004).
128. Cuatrecasas P. Drug discovery in jeopardy. J. Clin. Invest. 116(11), 2837-2842 (2006).